Porcilis PCV

Porcilis PCV is a biotechnology derived inactivated immunological veterinary medicinal product intended to be used for the active immunisation of pigs against Porcine Circovirus Disease (PCVD). First recognised in 1991 in Canada, Porcine Circovirus Type 2 (PCV2) is considered to be associated with a number of disease syndromes which have been collectively named PCVD. In particular, infection by PCV2 is nowadays recognised as the major risk factor in the establishment of the complex syndrome known as Post-weaning Multi-systemic Wasting Syndrome (PMWS) which affects principally piglets at the post-weaning and beginning of fattening stages. Porcilis PCV is administered via the intramuscular route in the neck in the area behind the ear to pigs from three days of age to reduce the virus load in blood and lymphoid tissues and to reduce weight loss associated with PCV2 infection occurring during the fattening period.